Few studies have summarized findings for the effect of metformin on obesity indices. Therefore, we aimed to conduct a systematic review and meta-analysis on the effect of metformin on obesity indices among children and adolescents.
Methods:
Relevant articles published up to September 2018 were searched in SCOPUS, Medline, and Google Scholar using appropriate keywords. All clinical trials that examined the effect of metformin on obesity indices in children and adolescents were included.
Results:
Overall, 38 studies, including 2199 participants (39.75% male and 60.25% female), were included. The pooled results indicated that metformin significantly reduced BMI [weighted mean difference (WMD): −1.07 kg/m2; 95% confidence interval (CI): −1.43 to −0.72]. Same findings were found for waist circumference (WC) (WMD: −1.93 cm; 95% CI: −2.69 to −1.16). Metformin also reduced body weight in all participants (WMD: −2.51 kg; 95% CI: −3.14 to −1.89). Moreover, it reduced body fat mass in patients with overweight or obesity (WMD: −1.90%; 95% CI: −3.25 to −0.56) and chronic diseases (WMD: −1.41%; 95% CI: −2.23 to −0.58), but not among those with growth problems. Metformin therapy did not affect lean body mass (LBM) in patients with overweight or obesity and growth problems; however, it reduced LBM in patients with chronic diseases (WMD: −1.49 kg; 95% CI: −2.69 to −0.30).
Conclusions:
We found a significant reduction in BMI, body weight, WC, and fat mass following administration with metformin. However, the effect of metformin on LBM was not significant. Further studies are required to confirm these findings.
Get full access to this article
View all access options for this article.
References
1.
GungorNK. Overweight and obesity in children and adolescents. J Clin Res Pediatr Endocrinol, 2014; 6:129–143.
2.
MellisC. Screening for obesity in children and adolescents. J Paediatr Child Health, 2018; 54:210.
3.
ShimobayashiM, AlbertV, WoelnerhanssenB, et al.Insulin resistance causes inflammation in adipose tissue. J Cli Invest, 2018; 128:1538–1550.
4.
CollinsKH-MC, HerzogW, MacDonaldGZ, et al.Obesity, metabolic syndrome, and musculoskeletal disease: Common inflammatory pathways suggest a central role for loss of muscle integrity. Front Physiol, 2018; 9:112.
5.
NgM, FlemingT, RobinsonM, et al.Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet, 2014; 384:766–781.
6.
AltmanM, WilfleyDE. Evidence update on the treatment of overweight and obesity in children and adolescents. J Clin Child Adolesc Psychol, 2015; 44:521–537.
7.
ConsoliA, GomisR, HalimiS, et al.Initiating oral glucose-lowering therapy with metformin in type 2 diabetic patients: An evidence-based strategy to reduce the burden of late-developing diabetes complications. Diabetes Metab, 2004; 30:509–516.
8.
Ladeiras-LopesR, Fontes-CarvalhoR, BettencourtN, et al.Novel therapeutic targets of metformin: Metabolic syndrome and cardiovascular disease. Expert Opin Ther Targets, 2015; 19:869–877.
9.
SeifarthC, SchehlerB, SchneiderHJ. Effectiveness of metformin on weight loss in non-diabetic individuals with obesity. Exp Clin Endocrinol Diabetes, 2013; 121:27–31.
10.
FreemarkM, BurseyD. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics, 2001; 107:E55.
11.
Evia-ViscarraML, Rodea-MonteroER, Apolinar-JiménezE, et al.The effects of metformin on inflammatory mediators in obese adolescents with insulin resistance: Controlled randomized clinical trial. J Pediatr Endocrinol Metab, 2012; 25:41–49.
12.
SarnbladS, KroonM, AmanJ. Metformin as additional therapy in adolescents with poorly controlled type 1 diabetes: Randomised placebo-controlled trial with aspects on insulin sensitivity. Eur J Endocrinol, 2003; 149:323–329.
13.
ParkMH, KinraS, WardKJ, et al.Metformin for obesity in children and adolescents: A systematic review. Diabetes Care, 2009; 32:1743–1745.
14.
Al KhalifahRA, AlnhdiA, AlgharH, et al.The effect of adding metformin to insulin therapy for type 1 diabetes mellitus children: A systematic review and meta-analysis. Pediatr Diabetes, 2017; 18:664–673.
15.
MaayanL, VakhrushevaJ, CorrellCU. Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: A systematic review and meta-analysis. Neuropsychopharmacology, 2010; 35:1520.
16.
HozoSP, DjulbegovicB, HozoI. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol, 2005; 5:13.
17.
AdeyemoMA, McDuffieJR, KozloskyM, et al.Effects of metformin on energy intake and satiety in obese children. Diabetes Obes Metab, 2015; 17:363–370.
18.
AnagnostouE, AmanMG, HandenBL, et al.Metformin for treatment of overweight induced by atypical antipsychotic medication in young people with autism spectrum disorder: A randomized clinical trial. JAMA Psychiatry, 2016; 73:928–937.
19.
ArmanS, SadramelyMR, NadiM, KoleiniN. A randomized, double-blind, placebo-controlled trial of metformin treatment for weight gain associated with initiation of risperidone in children and adolescents. Saudi Med J, 2008; 29:1130–1134.
20.
AtabekME, PirgonO. Use of metformin in obese adolescents with hyperinsulinemia: A 6-month, randomized, double-blind, placebo-controlled clinical trial. J Pediatr Endocrinol Metab, 2008; 21:339–348.
21.
BridgerT, MacDonaldS, BaltzerF, RoddC. Randomized placebo-controlled trial of metformin for adolescents with polycystic ovary syndrome. Arch Pediatr Adolesc Med, 2006; 160:241–246.
22.
BurgertTS, DuranEJ, Goldberg-GellR, et al.Short-term metabolic and cardiovascular effects of metformin in markedly obese adolescents with normal glucose tolerance. Pediatr Diabetes, 2008; 9:567–576.
23.
CasteelsK, AsscherickxW, van HelvoirtM, et al.metformin therapy to reduce weight gain and visceral adiposity in children and adolescents with neurogenic or myogenic motor deficit: O/2/wed/08. Pediatr Diabetes, 2009; 10:18.
24.
ClarsonCL, MahmudFH, BakerJE, et al.Metformin in combination with structured lifestyle intervention improved body mass index in obese adolescents, but did not improve insulin resistance. Endocrine, 2009; 36:141–146.
25.
DíazM, BassolsJ, López-BermejoA, et al.Metformin treatment to reduce central adiposity after prenatal growth restraint: A placebo-controlled pilot study in prepubertal children. Pediatr Diabetes, 2015; 16:538–545.
26.
El-SharkawyAA, AbdelmotalebGS, AlyMK, KabelAM. Effect of metformin on sleep disorders in adolescent girls with polycystic ovarian syndrome. J Pediatr Adolesc Gynecol, 2014; 27:347–352.
27.
Garibay-NietoN, Queipo-GarcíaG, AlvarezF, et al.Effects of conjugated linoleic acid and metformin on insulin sensitivity in obese children: Randomized clinical trial. J Clin Endocrinol Metab, 2016; 102:132–140.
28.
Gómez-DíazRA, TalaveraJO, PoolEC, et al.Metformin decreases plasma resistin concentrations in pediatric patients with impaired glucose tolerance: A placebo-controlled randomized clinical trial. Metabolism, 2012; 61:1247–1255.
29.
HamiltonJ, CummingsE, ZdravkovicV, et al.Metformin as an adjunct therapy in adolescents with type 1 diabetes and insulin resistance: A randomized controlled trial. Diabetes Care, 2003; 26:138–143.
30.
HoegerK, DavidsonK, KochmanL, et al.The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. J Clin Endocrinol Metab, 2008; 93:4299–4306.
31.
IbanezL, Lopez-BermejoA, DíazM, et al.Metformin treatment for four years to reduce total and visceral fat in low birth weight girls with precocious pubarche. J Clin Endocrinol Metab, 2008; 93:1841–1845.
32.
JonesKL, ArslanianS, PeterokovaVA, et al.Effect of metformin in pediatric patients with type 2 diabetes: A randomized controlled trial. Diabetes Care, 2002; 25:89–94.
33.
KayJP, AlemzadehR, LangleyG, et al.Beneficial effects of metformin in normoglycemic morbidly obese adolescents. Metab Clin Exp, 2001; 50:1457–1461.
34.
KendallD, VailA, AminR, et al.Metformin in obese children and adolescents: The MOCA trial. J Clin Endocrinol Metab, 2013; 98:322–329.
35.
KleinDJ, CottinghamEM, SorterM, et al.A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. Am J Psychiatry, 2006; 163:2072–2079.
36.
LavineJE, SchwimmerJB, Van NattaML, et al.Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: The TONIC randomized controlled trial. JAMA, 2011; 305:1659–1668.
37.
LibmanIM, MillerKM, DiMeglioLA, et al.Effect of metformin added to insulin on glycemic control among overweight/obese adolescents with type 1 diabetes: A randomized clinical trial. JAMA, 2015; 314:2241–2250.
38.
Love-OsborneK, SheederJ, ZeitlerP. Addition of metformin to a lifestyle modification program in adolescents with insulin resistance. J Pediatr, 2008; 152:817–822.
39.
LuongDQ, OsterR, AshrafAP. Metformin treatment improves weight and dyslipidemia in children with metabolic syndrome. J Pediatr Endocrinol Metab, 2015; 28:649–655.
40.
MaurasN, DelGiornoC, HossainJ, et al.Metformin use in children with obesity and normal glucose tolerance—Effects on cardiovascular markers and intrahepatic fat. J Pediatr Endocrinol Metab, 2012; 25:33–40.
41.
NadeauKJ, ChowK, AlamS, et al.Effects of low dose metformin in adolescents with type I diabetes mellitus: A randomized, double-blinded placebo-controlled study. Pediatr Diabetes, 2015; 16:196–203.
42.
NobiliV, MancoM, CiampaliniP, et al.Metformin use in children with nonalcoholic fatty liver disease: An open-label, 24-month, observational pilot study. Clin Ther, 2008; 30:1168–1176.
43.
NwosuBU, MarandaL, CullenK, et al.A randomized, double-blind, placebo-controlled trial of adjunctive metformin therapy in overweight/obese youth with type 1 diabetes. PLoS One, 2015; 10:e0137525.
44.
OngK, De ZegherF, VallsC, et al.Persisting benefits 12–18 months after discontinuation of pubertal metformin therapy in low birthweight girls. Clin Endocrinol, 2007; 67:468–471.
45.
Pastor-VillaescusaB, CañeteMD, Caballero-VillarrasoJ, et al.Metformin for obesity in prepubertal and pubertal children: A randomized controlled trial. Pediatrics, 2017; 140:e20164285.
46.
RezvanianH, HashemipourM, KelishadiR, et al.A randomized, triple masked, placebo-controlled clinical trial for controlling childhood obesity. World J Pediatr, 2010; 6:317–322.
47.
RyndersC, WeltmanA, DelgiornoC, et al.Lifestyle intervention improves fitness independent of metformin in obese adolescents. Med Sci Sports Exerc, 2012; 44:786.
48.
Van der AaM, ElstM, Van De GardeE, et al.Long-term treatment with metformin in obese, insulin-resistant adolescents: Results of a randomized double-blinded placebo-controlled trial. Nutr Diabetes, 2016; 6:e228.
49.
WiegandS, l'AllemandD, HübelH, et al.Metformin and placebo therapy both improve weight management and fasting insulin in obese insulin-resistant adolescents: A prospective, placebo-controlled, randomized study. Eur J Endocrinol, 2010; 163:585–592.
50.
WilsonDM, AbramsSH, AyeT, et al.Metformin extended release treatment of adolescent obesity: A 48-week randomized, double-blind, placebo-controlled trial with 48-week follow-up. Arch Pediatr Adolesc Med, 2010; 164:116–123.
51.
YanovskiJA, KrakoffJ, SalaitaCG, et al.Effects of metformin on body weight and body composition in obese insulin-resistant children: A randomized clinical trial. Diabetes, 2011; 60:477–485.
52.
McDonaghMS, SelphS, OzpinarA, FoleyC. Systematic review of the benefits and risks of metformin in treating obesity in children aged 18 years and younger. JAMA Pediatr, 2014; 168:178–184.
53.
PraharajSK, JanaAK, GoyalN, SinhaVK. Metformin for olanzapine-induced weight gain: A systematic review and meta-analysis. Br J Clin Pharmacol, 2011; 71:377–382.
54.
DuY, ZhuH, ZhengS, et al.Age and sex effects on the relationship between body composition and hip geometric structure in males and females from East China. Arch Osteoporos, 2018; 13:79.
55.
MalinSK, KashyapSR. Effects of metformin on weight loss: Potential mechanisms. Curr Opin Endocrinol Diabetes Obes, 2014; 21:323–329.
56.
ChiltonM, DunkleyA, CarterP, et al.The effect of antiobesity drugs on waist circumference: A mixed treatment comparison. Diabetes Obes Metab, 2014; 16:237–247.
57.
SiskindDJ, LeungJ, RussellAW, et al.Metformin for clozapine associated obesity: A systematic review and meta-analysis. PLoS One, 2016; 11:e0156208.
58.
Chau-VanC, GambaM, SalviR, et al.Metformin inhibits adenosine 5′-monophosphate-activated kinase activation and prevents increases in neuropeptide Y expression in cultured hypothalamic neurons. Endocrinology, 2007; 148:507–511.
59.
AubertG, MansuyV, VoirolM-J, et al.The anorexigenic effects of metformin involve increases in hypothalamic leptin receptor expression. Metabolism, 2011; 60:327–334.
60.
McCreightLJ, BaileyCJ, PearsonER. Metformin and the gastrointestinal tract. Diabetologia, 2016; 59:426–435.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
